The event, hosted by Outsourced Pharma and Life Science Connect, selects companies demonstrating outstanding performance in capabilities, compatibility, expertise, quality, reliability and service, based on evaluations by decision-makers at global pharmaceutical and biotech companies with collaboration experience over the past two years. Starting this year, an independent review by the Tufts Center for the Study of Drug Development (Tufts CSDD) has also been incorporated.
Lotte Biologics Co., Ltd. was named winner in the “Best New or Relaunched CDMO” category, a judges’ award. The category recognizes companies that have successfully entered the market or restructured their operations and earned strong trust from global partners based on differentiated competitiveness and clear strategic direction.
The company said the award is meaningful as an achievement made within four years of its launch, noting that it reflects both the rapid expansion of brand recognition in the global market and direct recognition from clients of its CDMO service quality and execution capabilities.
Industry observers are paying attention to Lotte Biologics’ “dual site” strategy. The company has demonstrated competitiveness by earning strong trust and positive evaluations from global clients, backed by experience with approvals from more than 62 global regulatory authorities and an expanded focus on antibody-drug conjugate (ADC) modalities.
Lotte Biologics is expected to rapidly expand its business portfolio—from antibody therapeutics to ADCs—based on its first plant at the Songdo Bio Campus in Asia, scheduled for completion in August this year, positioning itself as a key player in the next-generation biopharmaceutical market.
A Lotte Biologics official said, “It is very meaningful to receive a globally recognized award as a CDMO company within a short period since our launch,” adding, “We will continue to strengthen our role and responsibility as a leading company that delivers tangible value to the global biopharmaceutical ecosystem beyond simple growth in scale.”